Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

PURPOSE: Treatment options for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) represent an unmet medical need. Apatinib is a new oral tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumour angiogenesis. In the present stu...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Drug Des Devel Ther
Main Authors: Ma, Xinran, Li, Ling, Zhang, Lei, Fu, Xiaorui, Li, Xin, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Feng, Xiaoyan, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Zhang, Jieming, Li, Zhaoming, Zhang, Mingzhi
Format: Artigo
Sprog:Inglês
Udgivet: Dove 2020
Fag:
Clinical Trial Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6986930/
https://ncbi.nlm.nih.gov/pubmed/32158186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S227477
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker